Foundation Medicine adds new immunotherapy features to its gene profiling products

Foundation Medicine hopes to enhance oncologist insight into potential immunotherapy responses with the addition of new clinical markers to its FoundationOne and FoundationOne Heme products.
The firm is adding the ability to determine Tumour Mutational Burden (TMB) and Microsatellite Instability MSI) from its assays in addition to the comprehensive profiling of genes provided by the two products.
read more